UC
UCB
UCB.BR·EBRBrussels BEFounded 19288,700 employees
Large CappharmaPublicNeurologyImmunology
Platform: Bimekizumab
Market Cap
$22B
All Drugs
7
Clinical Trials
12
Failed / Terminated
5
FDA Approved
1
Stock Price & Catalysts (UCB.BR)
Loading UCB.BR stock data...
Drug Pipeline (7 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Sovafotisoran | UCB-1180 | NDA/BLA | 1 | FGFR | NBLN | ||
| UCB-6099 | UCB-6099 | Approved | 2 | SHP2 | AngelmanFabry | ||
| UCB-8638 | UCB-8638 | Phase 1 | 2 | SGLT2 | GA | ||
| UCB-7877 | UCB-7877 | NDA/BLA | 2 | KIF18A | SMANMOSD | ||
| UCB-7696 | UCB-7696 | NDA/BLA | 1 | GIP-R | SCLC | ||
| Lisosotorasib | UCB-9207 | NDA/BLA | 2 | Menin | Wilms | ||
| Talafutibatinib | UCB-8427 | Phase 1/2 | 2 | TROP-2 | CF |
SEC Filings & Financial Documents
SEC filings are not available for EBR-listed companies.
UCB trades on EBR (BE). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (12)